Verweij J - Search Results

1

[Developments in chemotherapy; cytostatic agents with an increased specificity and other forms of administering cytotoxic antineoplastic agents].

Eskens FA, de Jonge MJ, Verweij J. Eskens FA, et al. Among authors: verweij j. Ned Tijdschr Geneeskd. 2001 Nov 17;145(46):2208-13. Ned Tijdschr Geneeskd. 2001. PMID: 11757242 Review. Dutch.

2

Farnesyl transferase inhibitors: current developments and future perspectives.

Eskens FA, Stoter G, Verweij J. Eskens FA, et al. Among authors: verweij j. Cancer Treat Rev. 2000 Oct;26(5):319-32. doi: 10.1053/ctrv.2000.0187. Cancer Treat Rev. 2000. PMID: 11006134 Review.

3

Matrix metalloproteinase inhibitors: current developments and future perspectives.

Hoekstra R, Eskens FA, Verweij J. Hoekstra R, et al. Among authors: verweij j. Oncologist. 2001;6(5):415-27. doi: 10.1634/theoncologist.6-5-415. Oncologist. 2001. PMID: 11675519 Free article. Review.

4

The use of oral cytotoxic and cytostatic drugs in cancer treatment.

Sparreboom A, de Jonge MJ, Verweij J. Sparreboom A, et al. Among authors: verweij j. Eur J Cancer. 2002 Jan;38(1):18-22. doi: 10.1016/s0959-8049(01)00322-7. Eur J Cancer. 2002. PMID: 11750835

5

Renal toxicities of chemotherapy.

de Jonge MJ, Verweij J. de Jonge MJ, et al. Among authors: verweij j. Semin Oncol. 2006 Feb;33(1):68-73. doi: 10.1053/j.seminoncol.2005.11.011. Semin Oncol. 2006. PMID: 16473645 Review.

6

The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review.

Eskens FA, Verweij J. Eskens FA, et al. Among authors: verweij j. Eur J Cancer. 2006 Dec;42(18):3127-39. doi: 10.1016/j.ejca.2006.09.015. Epub 2006 Nov 13. Eur J Cancer. 2006. PMID: 17098419 Review.

7

Danusertib, an aurora kinase inhibitor.

Meulenbeld HJ, Mathijssen RH, Verweij J, de Wit R, de Jonge MJ. Meulenbeld HJ, et al. Among authors: verweij j. Expert Opin Investig Drugs. 2012 Mar;21(3):383-93. doi: 10.1517/13543784.2012.652303. Epub 2012 Jan 13. Expert Opin Investig Drugs. 2012. PMID: 22242557 Review.

8

Moving molecular targeted drug therapy towards personalized medicine: issues related to clinical trial design.

Verweij J, de Jonge M, Eskens F, Sleijfer S. Verweij J, et al. Mol Oncol. 2012 Apr;6(2):196-203. doi: 10.1016/j.molonc.2012.01.009. Epub 2012 Feb 16. Mol Oncol. 2012. PMID: 22386481 Free PMC article. Review.

9

Clinical trial design for target specific anticancer agents.

Hoekstra R, Verweij J, Eskens FA. Hoekstra R, et al. Among authors: verweij j. Invest New Drugs. 2003 May;21(2):243-50. doi: 10.1023/a:1023581731443. Invest New Drugs. 2003. PMID: 12889742 Review.

10

Topoisomerase I inhibitors: the relevance of prolonged exposure for present clinical development.

Gerrits CJ, de Jonge MJ, Schellens JH, Stoter G, Verweij J. Gerrits CJ, et al. Among authors: verweij j. Br J Cancer. 1997;76(7):952-62. doi: 10.1038/bjc.1997.491. Br J Cancer. 1997. PMID: 9328159 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

929 results

Search Page

Filters